Evidence map›Paper›PMID 30811507›Full record

ArticlePloS one2019

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells.

Zachary D Nagel, Andrew A Beharry, Patrizia Mazzucato, Gaspar J Kitange, Jann N Sarkaria, Eric T Kool, Leona D Samson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zachary D NagelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.ORCID 0000-0003-2104-2093
Andrew A BeharryDepartment of Chemistry, Stanford University, Stanford, California, United States of America.
Patrizia MazzucatoDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Gaspar J KitangeDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, United States of America.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, United States of America.
Eric T KoolDepartment of Chemistry, Stanford University, Stanford, California, United States of America.
Leona D SamsonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Massachusetts Institute of Technology · USMayo Clinic · USStanford University · US

Funding

Measuring and Modulating Oxidative DNA Damage Surveillance PathwaysR01CA217809 · NCI · STANFORD UNIVERSITY · PI KOOL, ERIC T. · 2017 to 2024
$3.7M
NCI NIH HHS R01 CA217809
6 · The paper itself

Abstract

The DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) strongly influences the effectiveness of cancer treatment with chemotherapeutic alkylating agents, and MGMT status in cancer cells could potentially contribute to tailored therapies for individual patients. However, the promoter methylation and immunohistochemical assays presently used for measuring MGMT in clinical samples are indirect, cumbersome and sometimes do not accurately report MGMT activity. Here we directly compare the accuracy of 6 analytical methods, including two fluorescent reporter assays, against the in vitro MGMT activity assay that is considered the gold standard for measuring MGMT DNA repair capacity. We discuss the relative advantages of each method. Our data indicate that two recently developed fluorescence-based assays measure MGMT activity accurately and efficiently, and could provide a functional dimension to clinical efforts to identify patients who are likely to benefit from alkylating chemotherapy.

Indexed as

Antineoplastic Agents, AlkylatingBiological AssayCell LineDNA MethylationDNA Modification MethylasesDNA RepairDNA Repair EnzymesFluorescent DyesHumansPromoter Regions, GeneticTumor Suppressor ProteinsAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesFluorescent DyesMGMT protein, humanTumor Suppressor Proteins

Identifiers

PMID30811507
PMCPMC6392231
OpenAlexW2917424202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.